Quanterix Q1 Earnings Forecast Adjusted by Leerink Partners

Quanterix Co. (NASDAQ:QTRX - Free Report) has had its Q1 2025 earnings per share (EPS) estimates lowered by analysts at Leerink Partners in a report released on Monday, March 17th. The firm's analyst, P. Souda, now predicts that Quanterix will report an EPS of ($0.69) for the upcoming quarter. This is a reduction from the previous estimate of ($0.58). Currently, the consensus expectation for the company's overall earnings this year stands at ($0.98) per share.

Additionally, Leerink Partners provided their estimates for future quarters, forecasting Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, and Q4 2025 earnings at ($0.22) EPS. For the entire fiscal year of 2025, they anticipate earnings of ($1.49) EPS. For 2026, the expected figures include a Q1 EPS of ($0.32), Q2 of ($0.28), Q3 of ($0.24), Q4 of ($0.21), and an overall FY2026 EPS of ($1.05).

In a separate report issued on Tuesday, Canaccord Genuity Group also adjusted their price target for Quanterix, reducing it from $20.00 to $15.00 while maintaining a "buy" rating for the company.

Quanterix Stock Performance

As of Thursday, shares of Quanterix opened at $7.20. Over the past year, the company has seen a low of $6.30 and a high of $27.37. Quanterix holds a market capitalization of $277.37 million, a PE ratio of -6.79, and a beta of 1.34. The stock's fifty-day moving average is $8.32, while the 200-day moving average stands at $10.90.

The last quarterly earnings results were published on March 17th, where Quanterix reported an EPS of ($0.30), falling short of analysts' consensus estimates of ($0.27) by $0.03. Revenue for the quarter was $35.16 million, which was slightly more than the expected $34.93 million. The company reported a negative return on equity of 11.74% and a negative net margin of 30.12%.

Institutional Investor Actions for Quanterix

Several hedge funds have recently altered their positions regarding Quanterix. For instance, GSA Capital Partners LLP entered a new position in Quanterix during the third quarter, with an investment of around $258,000. Similarly, Connor Clark & Lunn Investment Management Ltd. acquired a new stake valued at about $500,000. Additionally, Intech Investment Management LLC entered the stock with a $170,000 investment. Algert Global LLC boosted its holdings in Quanterix by 75.9% in the same quarter, now owning 137,833 shares worth approximately $1,786,000 following the acquisition of an additional 59,496 shares. FMR LLC also significantly increased its stake by 112.6%, holding 30,242 shares valued at around $392,000 after adding 16,020 shares. Hedge funds and institutional investors collectively own approximately 86.48% of Quanterix stock.

About Quanterix Corporation

Quanterix Corporation is a life sciences company specializing in digital immunoassay platforms designed to enhance precision health in life sciences research and diagnostics. The company operates in various regions, including North America, Europe, the Middle East, Africa, and Asia Pacific. Quanterix offers products such as the HD-X instrument, which is a protein detection platform, and the SR-X instrument, which enables the application of Simoa detection across a broader range of uses.

Earnings, Forecast, Stocks, Analysis